Cereno, PHA Europe partner on patient-centered PH drug design
WHY IT MATTERS
Patients with pulmonary hypertension will now have direct input into how new treatments are designed, potentially resulting in drugs that better address their real-world needs and concerns.
A company called Cereno Scientific is working with PHA Europe & Global to design new pulmonary hypertension medicines in a way that includes patient input. Instead of just scientists deciding how to develop drugs, patients with pulmonary hypertension will have a say in the process from start to finish. This partnership means the final medications may work better for the people who actually need them.
A new partnership aims to incorporate more patient perspectives into the development of medications for pulmonary hypertension (PH). Cereno Scientific will partner with PHA Europe & Global on a patient-centered drug design project. Patient-centered drug development enables people affected by a disease to contribute throughout the development and evaluation of medications for the condition. Patient communities […] The post Cereno, PHA Europe partner on patient-centered PH drug design ap